Mechanism of action of glucocorticoids in nasal polyposis  by Fernandes, Atílio Maximino et al.
279
Brazilian Journal of otorhinolaryngology 74 (2) March/april 2008
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
Mechanism of action of 
glucocorticoids in nasal 
polyposis 
   Summary
Atílio Maximino Fernandes 1, Fabiana Cardoso 
Pereira Valera 2, Wilma T. Anselmo-Lima 3
 1 Doctor, USP/Ribeirão Preto, Otorhinolaryngologist.
 2 Doctor, Professor.
 3 Livre-docente habilitation, Professor.
Paper submitted to the ABORL-CCF SGP (Management Publications System) on August 4th, 2006 and accepted for publication on March 24th, 2007. cod. 3315.
Glucocorticoids (GC) are the drugs of choice for the 
clinical treatment of nasal polyposis, according to the medical 
literature. Its mechanism of action in the regression of clinical 
symptoms and polyps, however, is not fully understood. The 
topical and/or systemic use of glucocorticoids lead to variable 
expression of cytokines, chemokines and lymphokines, as 
well as changes in cells. It is known that GC suppresses the 
expression of pro-inflammatory cytokines, chemokines and 
adhesion molecules such as ICAM-1 and E-selectin; GC also 
stimulate the transcription of anti-inflammatory cytokines 
such as TGF-&#946;. GC suppress pro-fibrotic cytokines 
related to polyp growth, such as IL-11, the basic fibroblast 
growth factor (b-FGF), and the vascular endotelial growth 
factor (VEGF). The action of GC depends fundamentally 
on their interaction with receptors (GR); certain subjects 
have a degree of resistance to its effect, which appears to 
be related with the presence of a &#946; isoform of GR. GC 
also act variably on the genes involved in immunoglobulin 
production, presentation, and antigen processing. Aim: We 
present a review of the literature on the mechanisms of GC 
action in nasal polyosis. Conclusion: Understanding the 
mechanism of action of GC in nasal polyposis will aid in the 
development of new, more efficient, drugs.
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INTRODUCTION
Glucocorticoids (GC) are steroid hormones deri-
ved from cholesterol metabolism. These hormones are 
effective immunosuppressant and anti-inflammatory 
agents, and are naturally produced in the adrenal glands 
upon stimulation by the hypothalamic-pituitary-adrenal 
axis (HPA). These steroid hormones are the main the-
rapeutic component in various autoimmune diseases 
such as rheumatoid arthritis, ulcerative colitis, asthma 
and polyposis.1
The fist successful use of hydrocortisone (the 
first GC metabolite that was synthesized) was in 1948; it 
was used for suppressing the clinical manifestations of 
rheumatoid arthritis. GC are used in nasosinal polyposis 
(NSP) in its topical or systemic forms, yielding excellent 
results by causing polypoid tissues to regress and by 
reducing inflammation. Clinical improvement occurs, 
with decreased respiratory obstruction and rhinorrhea, 
and improved olfaction. GC are first line drugs for the 
initial treatment of this condition, according to the Inter-
national Consensus on NSP in 20022 and the European 
Consensus in 2004;3 it’s efficacy has been demonstrated in 
various therapeutic models.4,5,6 Topical GC are preferable 
for long-term use due to minimal systemic absorption 
and fewer side-effects; their effect within the paranasal 
sinuses, however, is limited. GC have also been used 
routinely following polyp-removing surgical procedures 
for reducing the recurrence of polyps and increasing the 
interval between surgery in these patients, thus helping 
control NSP.6 GC may, however, not be effective in all 
cases; the success rate of this form of treatment is around 
60.9 to 80%.7,8 It is known that unsuccessful topical GC 
treatment is related to extensive NSP cases and lack of 
adhesion to therapy. The main factor that establishes the 
efficacy of GC therapy is the intrinsic, cell mechanism-
mediated, resistance to the drug.
The aim of this review was to discuss the possible 
cell action mechanisms of GC in NSP and their interactions 
with cytokines, chemokines and adhesion molecules.
 REVIEW OF THE LITERATURE
 
Molecular Mechanisms in NSP
NSP is a chronic inflammatory disease; its patho-
physiological mechanisms have not been fully unders-
tood, notwithstanding recognition of the histological 
changes that occur. These alterations are epithelial hyper-
plasia, increased goblet cell, basal membrane thickening, 
stromal edema, and increased fibroblast production, to 
which is added inflammatory cell recruitment including 
lymphocytes, plasmocytes and particularly eosinophils.6 
At a molecular level, cytokines - essential regu-
lating proteins for immune cell growth, differentiation 
and activation - influence NSP by two mechanisms: local 
tissue growth stimulation mediated by, for instance, b-
FGF, IGF-1, TGF-α, and TGF- β, and cytokine-mediated 
long-term maintenance of an inflammatory state involving 
IL-1β, TNF-α, IL-4, IL-5, IL-6, IL-10, and IFN-γ, among 
others.9 The complex interaction between these cytokines 
and structural and inflammatory cells leads to a chronic 
process that, after initiated, appears not to depend on 
the causal stimulus for its perpetuation.
It is known that fibroblasts and epithelial cells, 
once stimulated, are induced to produce TNFα and IL-1β. 
These cytokines stimulate nasal mucosa structural cells 
to produce various other cytokines (GM-CSF, IL-2, IL-3, 
IL-5, IL-6, IL-8, IL-12, IL-13, IL-16, TGF-α, TGF-β, TNF-α 
and IL-1 β), chemokines (RANTES, eotaxin, eotaxin-2) 
and adhesion molecules (ICAM-1 and VCAM-1). Cytokines 
activate inflammation, while chemokines and adhesion 
molecules are powerful circulating inflammatory cell - 
particularly eosinophils - recruiters. Once translocated 
to target tissues, these cells stimulate the production of 
other cytokines, which prolong and increase inflamma-
tion and produce cytotoxic molecules, such as the major 
basic protein (MBP), the eosinophilic cationic protein 
(ECP), leukotrienes and the platelet-activating factor 
(PAF). These molecules in turn intensify tissue damage, 
basal membrane thinning, stromal fibrosis, angiogenesis, 
and gland and stromal hyperplasia.6,10 Eosinophils are 
particularly able to produce cytokines - such as IL-3, IL-5 
and GM-CSF - that increase their survival and that recruit 
additional eosinophils into the polyps, thus intensifying 
tissue eosinophilia.11 
 
GC Action on Cell Composition and Activation
The anti-inflammatory action of GC results from a 
number of changes in inflammatory cells. Their use leads 
to an increase in the number of circulating neutrophils, 
decreased production of inflammatory lymphokines and 
monokines - such as IL-1 and TNF-α11 - and induction 
of eosinophils apoptosis.
Mastruzzo et al.12 found that intranasal GC increase 
the density of CD8+ cells in polyps, thereby decreasing 
the CD4/CD8 ratio. This author also observed decreased 
numbers of IL-5+ and IL-4+ cells, in contrast with an in-
creased number of TGF-β+ cells, which was correlated 
with CD8+ T-cells, and which is anti-inflammatory.12 
 
GC Intracellular action and on Inflammatory Media-
tors
The action mechanism of these substances on cells 
results from their bonding to cytoplasmic high-affinity 
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glucocorticoid receptors (GR). The steroid-receptor com-
plex (GC-GR) is capable of nuclear translocation; in the 
nucleus, it bonds with chromosomal DNA. This bond sets 
in motion or inhibits gene transcription, respectively by 
transactivation and transrepression. Transactivation is me-
diated by hormone-activated glucocorticoid receptor (or 
GC-GR complex) bonding to the DNA sequence named 
glucocorticoid response element (GRE). Corticosteroids, 
for instance, may stimulate anti-inflammatory molecule 
(IL-10, IL-1Rα6, TGF-β and IκB) and uteroglobulin syn-
thesis.
Benson9 used the microarray technique on 
glucocorticoid-treated polyps and showed that 200 of 
22,000 genes underwent some change in expression 
after treatment, and that these alterations were involved 
in various immunoglobulin-producing steps, in antigen 
presentation and processing, in chemoattraction, and in 
granulocyte and lymphocyte activation. The most highly 
expressed genes were those producing uteroglobulin and 
15-lipoxigenase, the latter being an enzyme that induces 
lipoxin production (signaling enzymes for inhibiting in-
flammation). Uteroglobulin inhibits leukocyte chemotaxis 
and phospholipase A2 and pro-inflammatory cytokines 
synthesis.9 
It is thought that most of the side effects of oral 
GC take place by gene transactivation. The main anti-
inflammatory effect of GC, however, is related to their 
transrepressor effect. Transrepression is specially media-
ted by direct protein-protein inhibition in the GC-GR com-
plex and by transcription factors such as AP-1 and NF-kB 
(cross-inhibition). When bonding with these factors, the 
GC-GR complex blocks the transcription of cytokines, 
chemokines and enzymes such as IL-18, IL-16 and eota-
xin, being thus directly related to their expresion.13
Transcription factors are cytoplasmatic molecules 
that upon activation are able to translocate to the nu-
cleus and to induce transcription of pro-inflammatory 
cytokines, adhesion molecules and chemokines, among 
others. GC, therefore, also suppress the transcription of 
pro-inflammatory cytokines (IL-1, IL-2, IL-3, IL-4, IL-, IL-6, 
GM-CSF, TNF-α, and IFN-γ), of chemokines (RANTES, 
eotaxin and MCP) and adhesion molecules (ICAM-1 and 
E-selectin).
Marx et al.14 found decreased GM-CSF and TNF-α 
levels in nasosinal polyps following in vitro glucocorticoid 
therapy. On the other hand, Hamilos et al.15 noted a ma-
rked decrease in GM-CSF, but not in TNF-α, in an in vivo 
study of fluticasone use during one month. Watanabe et 
al.11 also found decreased GM-CSF levels in nasal polyp 
epithelial cells under GC therapy, which would explain 
reduced eosinophil apoptosis.
Woodworth et al.16 demonstrated that IL-5 and 
IL-13 levels were significantly decreased in nasal polyps 
following systemic GC therapy in NSP patients. An even 
more significant reduction was observed after treatment 
with chemokines, eotaxin and MCP-4 (monocyte chemo-
attractant protein) in the same group of patients.
Silvestri et al.17 showed that fluticasone significan-
tly decreased β-FGF-induced fibroblast proliferation and 
TNF-α-induced ICAM-1 expression. This author also ob-
served TNF-α inhibition of eotaxin release and fibroblast 
inhibition within polyps due to IL-4.
Molet et al.18 showed that IL-11, a pro-fibrotic 
cytokine that stimulates fibroblast proliferation and smoo-
th muscle hyperplasia, is increased in nasal polyps. This 
elevation relative to the healthy mucosa occurs both in 
epithelial cells and in submucosal inflammatory cells, and 
is directly connected with type I collagen fiber accumu-
lation. Collagen types I and III typically accumulate in 
NSP, which is in line with the findings above. The same 
author also showed that following treatment of polyps 
with GC (fluticasone) during four weeks, IL-11 expression 
was markedly decreased. Uchida et al.19 demonstrated in 
vitro that, following treatment of polyps with fluticaso-
ne, there was suppression of mRNA expression of the 
basic fibroblast growth factor (bFGF) and the vascular 
endothelial growth factor. Yaritas et al.20 reported similar 
findings, noting decreased expression of bFGF in nasal 
polyps following the topical use of mometasone during 
four weeks in individuals with polyps.
Delbrouck et al.21 showed in vitro that budesonide 
can inhibit expression of the leukocyte migration inhi-
bitory factor (MIF), a lymphokine that counter-regulates 
GC, decreasing their expression in polyp epithelial and 
gland cells, depending on the concentration of GC.
There are two main cell resistance mechanisms 
against GC:
- the ratio between GRα/GRβ receptor isoforms
- transcription factors
There are two main GS isoform: GRα and GRβ. It is 
known that GRα is able to bind to GC after activating the 
GRE, after which it is considered as the active form. GRβ 
has the same GRE-binding capability, but does not bind to 
GC; GRβ, then, is considered an endogenous inhibitor of 
GC. Pujols et al.13 and Hamilos et al.15 reported increased 
GRβ expression in NSP patients, compared with controls. 
Valera10 and Li et al.22 observed lower GRα levels in NSP, 
compared to the normal mucosa. Both Pujols et al.13 and 
Valera10 stated that the most important factor in resistance 
to GC was the GRα/GRβ isoform ratio, more important 
then the absolute values of each isoform.
Increased expression of transcription factors is also 
important in the resistance to GC; when activated, these 
factors are able to directly inhibit bonding between GR 
and GC.23 
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Valera10 and Takeno et al.24 observed an increased 
expression of the p65 (active) and p50 (constitutional) 
NFκB fraction in nasal polyps, compared to the control 
mucosa. Valera10 showed that p65 levels decreased sig-
nificantly following the use of topical budesonide for 2 
months. This author also found a higher expression of p65 
in NSP cases that responded less to topical budesonide, 
compared to those cases that responded more favorably 
to medical therapy.
Baraniuk et al25 found that the AP-1 transcription 
factor c-fos (active) fraction was elevated in nasosinal 
polyps, and that c-fos expression in polyps was decrea-
sed following oral therapy with GC. Valera,10 however, 
showed that c-fos levels were not increased compared 
to the control nasal mucosa.
Further knowledge about the action of GC in 
NSP and the development of cell resistance mechanisms 
against these drugs increase the possibility that more 
specific and effective drugs may be developed for the 
treatment of NSP.
CONCLUSION
Systemic or topical corticosteroids are important 
drugs in the treatment of NSP, both singly in therapy 
and as adjuvant therapy in extensive cases that are also 
treated surgically. Their efficacy is still limited to 60-80% 
of cases.
Understanding the action mechanisms of GC in 
NSP may foster the development of more effective drugs 
for treating this condition.
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